title: Risperidone: a review of efficacy studies in adolescents with schizophrenia.
abstract: Risperidone has been approved by the Food and Drug Administration for the treatment of schizophrenia in the adolescent population. This new indication has been a result of data obtained from two pivotal double-blind trials with supplemental information from open-label and retrospective trials. This brief article provides an overview of risperidone's pharmacological profile followed by information on the double-blind trials that have resulted in the approval of risperidone for the treatment of adolescent schizophrenia.
authors.affiliation: Department of Psychiatry, Creighton University/University of Nebraska Medical Center, Omaha, Nebraska 68131, USA. vishalmadaan@creighton.edu
authors.forename: Vishal
authors.initials: V
authors.lastname: Madaan
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D018967:Risperidone / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone